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Abstract 
Background: The use of antimalaria combination therapy especially regimens containing an artemisin-based 
compound has been recommended as a good first-line treatment for malaria by WHO. However, limited reports 
exist on the effects of the ACT and other antimalarial drugs on some vital biological parameters such as G6PD 
activity and haemoglobin concentration. In this study, we investigated the effects of Artemeter-Lumefantrine, 
sulphadoxine-pyrimetamine combination therapies and Halofantrine monotherapy on G6PD activity, 
Haemoglobin level and parasite clearance rate in malaria-infected adults treated with the drugs in Enugu, 
Nigeria. Methodology: Forty malaria-infected adults aged between 20 and 30 years were used. The subjects 
were divided into four groups (A, B, C and D). The groups A, B and C were given Artemeter-Lumefantrine, 
sulphadoxine-pyrimetamine and halofantrine respectively, while group D was a control group (malaria-positive 
control). Blood samples of the subjects were collected through venepuncture at baseline (Day 0) and after 
treatment on Day 4, for comparative analysis of G6PD activity, haemoglobin concentration and parasite 
clearance for each group. Results: The result of this study showed that sulphadoxine-pyrimetamine significantly 
(p<0.05) lowered haemoglobin concentration as compared with Halofantrine, Artemeter-lumefantrine and 
control. The haemoglobin concentration of the last three groups did not show any significant difference (p>0.05) 
between each other. The G6PD activity of the group treated with sulphadoxine-pyrimetamine was significantly 
(p<0.05) higher as compared with that treated with Artemeter-lumefantrine but non-significant (p>0.05) as 
compared with halofantrine and control. Parasite clearance rate was significantly (p<0.05) highest with the 
Halofantrine group (76%, p< 0.05) while Sulphadoxine-pyrimetamine had the lowest (52%) parasite clearance. 
Conclusion: This study therefore indicated that antimalaria drugs as well as malaria parasite could cause a 
reduction in haemoglobin concentration with sulphadoxine-pyrimetamine causing significant (p<0.05) increase 
in G-6-PD activity. 
Keywords: Antimalarials, Artemether-Lumefantrine, G6PD, sulphadoxine-pyrimetamine, Parasite clearance, 
Halofantrine, Haemoglobin concentration 
 
1. Introduction 
Malaria affects half of the world’s population and is the third leading causes of death for children less than five 
years worldwide [WHO, 2011]. Africa including Nigeria is one of the countries most affected by malaria and 
accounts for 25 per cent of global malaria cases (WHO, 1996; WHO, 2011). It is estimated that about 97% of 
Nigeria’s population are at risk of malaria. According to data from Carter Centre for Malaria Control 
Programme, over 300,000 Nigerians—mostly children—die from malaria attack each year [WHO, 2011]. 
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Several reports of increasing incidence of drug resistant malaria parasites is of serious concern and which is 
responsible for the increasing cases of malaria in Africa [Roll Back Malaria Partnership Secretariat, 2010; 
Korenrop et al, 2004]. In an attempt to improve malaria treatment efficacy and reduce malaria parasite resistance 
to antimalarial drugs, the World Health Organization has advocated the use of Artemisinin-based combination 
therapy (ACT) and other combination therapy for the treatment of malaria [Olurishe et al., 2007]. Scientific 
reports have shown that ACTs are preferred because artemisin compounds have rapid parasite and fever 
clearance effects and reduce gametocyte rate with the potential to reduce transmission (Meremikwu, et al., 
2012). Artemether (artemesin-base) and lumenfantrine are blood schizontocides. Artemether is rapidly 
metabolized into an active metabolite dihydroartemisinin (DHA) (Medilexicon, 2013). The anti-malarial activity 
of artemether and DHA has been attributed to endoperoxide moiety (Medilexicon, 2013; Pandey et al., 1999) 
Hoppe et al., 2004). The exact mechanism by which lumefantrine, exerts its anti-malarial effect is not well defined 
(Medilexicon, 2013). However, available data suggests lumefantrine inhibits the formation of hematin by forming 
a complex with hemin (Medilexicon, 2013). Halofantrine presently is used as an antimalarial monotherapy in the 
form of halofantrine-hydrochloride (Glaxosmithkline, 2006; Truste, 2013). Halofantrine like ACT and 
sulphadoxine-pyremethamine, is a blood schizontocide and acts against the asexual erythrocytic stage of malaria 
parasite but its mechanisms of action is not yet known (Truste, 2013; Shah et al., 2006). However, the lack of 
alternative drugs to artemisinin derivatives and their short half-lives and susceptibility to recrudescence, when 
given as monotherapy are the major drawbacks of the artemisinin derivatives [Dondorp, et al., 2009; Douglas et 
al.,, 2010; Phyo, et al., 2012]. 
There are poor reports on the in vivo effects of ACT, and sulphadoxine-pyrimetamine combination therapies as 
compared to halofantrine monotherapy on some vital biological parameters such as G6PD and haemoglobin 
concentration as well as their comparative efficacies in malaria parasite clearance. Few studies, which 
demonstrated the haematinic and G6PD effects of ACT, suphadoxine-pyremethamine and halofantrine to the 
best of my knowledge as at the time of this study, were conducted in vitro on infected RBC. Although in vitro 
studies can be used to evaluate what happens in humans; they exhibit natural differences in susceptibility to 
malarial infection. In this study, we therefore investigated the effects of Artemether-lumemfantrine, 
sulphadoxine-pyrimetamine combination therapies and Halofantrine monotherapy on G6PD activity, 
Haemoglobin level in malaria parasite infected adult humans. The comparative efficacies of these antimalarial 
drugs on parasite clearance were also evaluated as the three drugs are blood schizontocides (Shah et al., 2006; 
Truste, 2006; MediLexicon, 2013).  
2. STUDY DESIGN AND METHODOLOGY 
2.1 Subjects 
Forty human subjects within the ages of 20-30 years (mean age of 25years) with uncomplicated malaria were 
selected and used for the study. They were divided into four groups (A, B, C and D) comprising ten individuals 
in each group. Individuals with any form of G6PD deficiency (G6PD value of <6 µ/gHb), diabetics and pregnant 
women were excluded from the study. Informed consents of the subjects were obtained prior to their 
participation in the study and they were assured of their safety and privacy throughout the study. The subjects 
were free to withdraw from the study at any time they wished.  
2.2 Drug treatment 
Group A was given Combination Therapy consisting of Artemether/Lumefantrine supplied as coartem (Novartis) 
(20mg/120mg) respectively (four tablets were administered twice daily for three days). Group B was given 
Combination Therapy consisting of sulfadoxine/Pyrimetamine supplied as malareich (Medreich pharmaceutical 
company) (500 mg/25 mg) respectively, administered as 3 tablets in a single dose. The group C was given 
Halofantrine (250 mg) supplied as halfan (Glaxosmithkline Pharmaceutical Company) containing 233 mg of 
halofantrine base and 17 mg hydrochloride. Two tablets of this were administered 6 hourly making a total of 6 
tablets per day. The group D (control) was not given any drug during the study. 
2.3 Blood sample collection 
Before the commencement of treatment (Day 0), blood samples were collected from subjects in each group for 
the determination of parasite density (parasiteamia), haemoglobin concentration and G6PD enzyme activity at 
baseline. The drug treatment commenced on (Day 1) and lasted for three days. On (Day 4) another blood sample 
was collected from each subject in the four groups for the analysis of G6PD activity, haemoglobin concentration 
and parasite clearance rate. Five millilitres (5 ml) of blood was collected from each subject (before and after 
treatment) and poured into EDTA (ethylene di-amino tetra-acetic acid). Sample in the EDTA bottle was used for 
the analysis of G6PD enzyme activity, haemoglobin concentration and Parasite density. The blood was collected 
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2.4 Laboratory procedures 
G6PD enzyme activity was determined using spectrophotometric method of Horecker and Komberg, (Randox 
Laboratories Ltd, United Kingdom). Normal range of G6PD activity in erythrocyte as prescribed by Randox 
G6PD Kit (2010) is 6.97- 20.5 U/gHb. Baseline values outside this range were excluded. Haemoglobin 
concentration was determined by Cyanmethaemoglobin method as described by Ochei and KolHatkar (2008) 
and measured colourimetrically at 540 nm. Parasitaemia assessment was done using a thick film stained with 
giemsa. A minimum of 200 WBC were counted per slide of a sample. Malaria parasite density was determined 
by dividing the number of parasites counted by the number of WBCs x 8000/1 = parasites/ml of blood (WHO, 
1996; WHO, 2010). Blood films were considered negative if no parasites were seen in 100 oil-immersion fields 
in a thick blood film.  
2.5 Statistical analysis 
Data was expressed as mean ± standard deviation. Comparative analysis involving four treatment groups and 
other variables were done using two-way ANOVA. Statistical significance was set at P<0.05. All statistics were 
carried out using GenStat Discovery Edition. 
3. Results 
Data obtained in this study showed that sulfadoxine-Pyrimetamine (sulpha/pyrem) significantly (p<0.05) 
lowered haemoglobin concentration as compared with artemether-lumefantrine (ART/LUME), halofantrine and 
control. The haemoglonin concentration of ART/Lume, halofantrine and control groups differed 
non-significantly (p>0.05) between each other (Figure 1). All the groups except the Art/lume group, showed 
non-significant (p>0.05) decrease in haemoglobin concentration after three days of treatments (Day 4) as 
compared with the baseline haemoglobin level. In other words, the ART/Lume group showed a statistically 
non-significant increase (p>0.05) in haemoglobin concentration after treatment (Figures 1, Tables 2, 3, 4 and 5).  
The G6PD activity of the group treated with sulpha/pyrem was significantly (p<0.05) higher than the group A 
treated with ART/Lume, but non-significant (p>0.05) as compared with the group B treated with halofantrine 
and control. Of all the groups, only the sulpha/pyrem group had significant (p<0.05) increase in G6PD activity 
after the treatment (Figure 2, Tables 2, 3, 4 and 5). 
All the antimalarial drugs significantly (p<0.05) cleared the malaria parasites after 3 days of treatment as 
compared with the baseline and control. The control had a non-significant (p>0.05) increase in the number of 
parasites per millilitre of blood as compared with the initial number. Halofantrine showed the highest percentage 
(76%) of parasitic clearance, then Artemether-lumefantrine (72%) with sulfadoxine-Pyrimetamine having the 
least percentage (52%) clearance (Figure 3, Tables 1, 2, 3, 4, and 5). Comparing the efficacies of the three 
antimalarial drugs used in this study in malaria parasite clearance, the result showed that there is no statistically 
significant (p>0.05) difference between the efficacies of Artemether-lumefantrine and Halofantrine but those two 
drugs differed significantly (p<0.05) from the efficacy of sulfadoxine-Pyrimethamine (Figure 3). 
4.0 Discussion 
Malaria is a systemic disease caused by infection of the red blood cells (RBCs) with intracellular 
protozoan parasites of the genus Plasmodium. The parasites are inoculated into the human host by a feeding 
female Anopheles mosquito (WHO, 1996). Clinical and scientific reports have shown that malaria parasites have 
developed increased resistance to antimalarial drugs. Ensue of the increase in resistance by these parasites, 
antimalaria combination therapy especially artemesin-based combination therapy has been recommended (WHO, 
2011). Our findings in this study on the efficacy of some antimalarial drugs (Both combination therapy and 
monotherapy) showed that halofantrine monotherapy (76%) was the most effective in parasite clearance, and 
then followed by ACT (Artemeter-lumenfantrine) combination therapy (72%). Sulphadoxine-pyremethamine 
combination therapy (52%) was the least effective in parasite clearance (Table 1). However, data analysis using 
two-way ANOVA revealed that the parasite clearance rates of the ACT and halofantrine as seen in this study 
were not significantly different from each other, but both were significantly (p<0.05) more effective in parasite 
clearance as compared with sulphadoxine-pyremethamine. This finding indicates that not all combination 
therapy is very effective in malaria treatment rather some antimalarial monotherapy could be more effective as 
observed in this study (Table 1). The high parasite clearance rate (76%) of halofantrine as observed in this study 
is consistent with the report of Glaxosmithkline, (2006), which showed that halofantrine had parasite clearance 
rate of 90% and 99% in two separate studies. The low parasite clearance rate of sulphadoxine-pyremethamine is 
attributable to possible resistance to the drug. Our findings in this study agree with the report of Shah et al., 
(2006) that sulphadoxine-pyremethamine failed in treatment of malaria parasite infections but 
artemether-lumenfantrine was effective in malaria treatment.  
Malaria parasites residing in the host erythrocytes, endocytose large amounts of the surrounding RBC 
cytoplasm through an invagination of the parasite plasma membrane called cytostome (Hoppe et al., 2004). The 
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endocytosed host RBC cytoplasm consist almost entirely of haemoglobin and can be digested in the food 
vacuole (Hoppe et al., 2004). The findings of this study showed that control group (untreated malaria positive 
subjects) had a non-significant (p>0.05) decrease in haemoglobin concentration after 3 days of monitoring 
(Figure 1 and Table 5). The decrease in haemoglobin concentration is consistent with the report by Hoppe et al., 
(2004). The non-significant decrease in haemoglobin concentration of this group is attributable to the 
uncompleted state of the malaria parasite infections during the study. Of the three groups administered different 
antimalarial drugs, only the group treated with artemesin-based combination therapy (Artemether-lumenfantrine) 
showed an increase in haemoglobin concentration after 3 days of treatment. The increase in haemoglobin 
concentration of the group treated with Artemether-lumenfantrine is consistent with the reports of Hoppe et al., 
(2004) and Pandey et al., (1999) and attributable to the endoperoxide activity of artemesin-based combination 
therapy which has been reported to inhibit haemoglobin degradation in malaria parasite infected RBC. The 
decrease in haemoglobin concentration observed in the groups treated with sulphadoxine-pyremethamine and 
halofantrine is attributable to their inability to inhibit endocytosis of host RBC cytoplasm. The non-significant 
nature of the drop in haemoglobin level among those groups treated sulpha/pyrem and halofantrine is possibly 
due to the significant (p<0.05) reduction in parasitemia after the 3 days of treatment. The higher percentage 
(1.57%) drop in haemoglobin level in the group treated with sulphadoxine-pyremethamine as compared with the 
group treated with halofantrine (0.65%) drop in haemoglobin level, could be attributed to the lower rate (52%) of 
parasite clearance by the sulpha/pyrem as compared with that observed in the group treated with halofantrine 
(76%) (Table 1). Also, these two drugs may have possibly stimulated endocytosis of the host RBC by the 
parasites leading to decrease in host haemoglobin. Hoppe et al., (2004) carried out an in vitro study with 
chloroquine and observed that the drugs increased endocytosis of host RBC by malaria parasites with reduction 
of host haemoglobin concentration. Therefore our finding in this present study with respect to halofantine and 
sulphadoxine-pyremethamine agrees with the report of the above study. The above inference is because the more 
parasite present in host RBC, the more endocytosis of host RBC cytoplasm and consequent degradation of host 
haemoglobin (Pandey et al., 1999). 
 Some antimalarial drugs including artemesin based combination drugs have been reported to lower blood 
glucose level (Ewenighi et al., 2013; Olayemi et al, 2012). The enzyme, glucose IV phosphate dehydrogenase is 
known to play a key role in glucose metabolism and protects red blood cells from oxidative injury of drugs and 
other oxidants (Ewenighi et al., 2013; Abdoulaye et al, 2010). Our findings in this present study showed a 
significant (p<0.05) increase in G6PD activity in the groups treated sulphadoxine-pyremethamine combination 
therapy but no significant (p>0.05) increase in the control group and groups treated with ART/lume combination 
and Halofantrine monotherapies, before and after treatment (Figure 2; Tables 2, 3, 4 and 5). The findings 
indicate that sulphadoxine-pyremethamine combination therapy have haemolytic adverse effects on the patients 
with G6PD sufficient individuals and could cause anaemia in such peoples if not well managed like in G6PD 
deficient individuals as reported by Shah et al., (2006). The haemolytic effects of sulphadoxine-pyremethamine 
could cause oxidative stress in the host and is attributable to the significant (p<0.05) increase in G6PD activity 
observed in the group treated with the drug. The increase in G6PD activity is possibly to protect the red cells 
against such oxidative injury as G6PD is known to plays key roles in protecting host RBC (Abdoulaye et al., 
2010). The lack of significant difference in G6PD activity in the groups treated with ART/lume and halofantrine 
agrees with the reports of Ewenighi et al., (2013) that ACT and amodaquine monotherapy have no adverse 
haemolytic effects on patients. 
5 Conclusions 
The findings of this study indicated that antimalarial drugs as well as malaria parasite possess the 
potential to reduce haemoglobin concentration and increase in G6PD activity which is significant with 
sulphadoxine-pyrimetamine. All the drugs used significantly (p<0.05) cleared malaria parasites after 3 days of 
treatment, with halofantrine being the most effective. We therefore recommend that further studies on these 
drugs be extended to 28 days or minimum of 14 days. 
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Table 1: The percentage malaria parasite clearance in patients treated with Artemether/ 
lumefantrin, Sulfadoxine/Pyrimethamine and Halofantrine drugs 
Drugs Before 
Treatment 
After 
Treatment 
Mean 
Difference 
% 
Clearance 
Artemether-lumefantrine 5720±539 1620±421 4100 72% 
Sulfadoxine-Pyrimethamine 6100±810 2940±1218 3160 52% 
Halofantrine 6050±1066 1480±625 4570 76% 
Control 6400±775 7070±879 670 10% 
increase 
Table 2: G6PD activity, Haemoglobin concentration and malaria parasite density before and 
after treatment in subjects treated with Artemether/lumefantrin drug 
Variables Before 
Treatment  
After Treatment Mean 
Difference 
P-value 
(Significnce) 
G6PD Activity 
(µ/gHb) 
7.99±1.9 8.12±1.9 0.13 p>0.05 
Haemoglobin 
(g/dl) 
13.00±1.55 13.02±1.51 0.02 p>0.05 
Parasites/ml of 
blood 
5720±539 1620±421 4100 P<0.05 
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Table 3: G6PD activity, Haemoglobin concentration and malaria parasite density before and 
after treatment in subjects treated with Sulfadoxine/Pyrimethamine drug 
Variables Before 
Treatment  
After Treatment Mean 
Difference 
P-value 
(Significnce) 
G6PD Activity 
(µ/gHb) 
9.00±1.1 10.86±1.5 1.86 P<0.05 
Haemoglobin 
(g/dl) 
12.11±1.41 11.92±1.47 0.19 p>0.05 
Parasites/ml of 
blood 
6100±810 2940±1218 3160 P<0.05 
 
Table 4: G6PD activity, Haemoglobin concentration and malaria parasite density before and 
after treatment in subjects treated with Halofantrine drug 
Variables Before 
Treatment  
After Treatment Mean 
Difference 
P-value 
(Significnce) 
G6PD Activity 
(µ/gHb) 
8.99±1.7 9.18±1.6 0.19 p>0.05 
Haemoglobin 
(g/dl) 
13.71±1.47 13.62±1.41 0.09 p>0.05 
Parasites/ml of 
blood 
6050±1066 1480±625 4570 P<0.05 
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Table 5: G6PD activity, Haemoglobin concentration and malaria parasite density of Malaria 
Patients without treatment after 3 days of initial Laboratory Diagnosis (Control group) 
Variables Initial Diagnosis  After 3 days Mean 
Difference 
P-value 
(Significnce) 
G6PD Activity 
(µ/gHb) 
9.11 9.13 0.02 p>0.05 
Haemoglobin 
(g/dl) 
14.04±1.54 13.47±1.49 0.57 p>0.05 
Parasites/ml of 
blood 
6400±775 7070±879 670 P>0.05 
Key: *P>0.05 = Non-significant; P<0.05 = Significant 
 
 
